The semaglutide weight-reduction label describes the population that produced its adverse-reaction table: 2,116 adults, mean age 48, 71% female. In the individual trials behind it the skew runs wider still — 74% female in the 68-week trial of adults without diabetes, 81% female in the trial that added intensive behavioral therapy, 79% female at randomization in the withdrawal trial.[1] The tirzepatide weight-reduction pool is 37% male, and its largest trial enrolled 68% women.[2]
That is the first thing a man should know about the numbers he is being sold. They were measured, overwhelmingly, in women.
The skew has a direction, and it flips with the endpoint
Move to the trials where the endpoint is an event rather than a percentage of body weight and the composition inverts. The cardiovascular outcome trial of semaglutide enrolled 17,605 participants with a mean age of 61.6 and a mean body-mass index of 33.34, and 72.5% of them were men.[3] The two tirzepatide sleep apnea trials enrolled 234 and 235 adults with moderate to severe obstructive sleep apnea, 67% and 72% malerespectively.[2] The diabetes trials on both labels sit almost exactly on the line, at 51% female.[1][2]
This is not an accident of recruitment. It is what happens when enrollment follows who presents with the qualifying diagnosis. A 2026 systematic review assembled 47 articles from 25 unique cardiovascular outcome trials of newer glucose-lowering agents, more than 185,000 participants published between 2015 and 2025, and found women made up roughly one-third of them.[4] The same drug class is studied in a female-majority population for weight and a male-majority population for death, and almost nobody reads both tables.
On weight, men do measurably worse
A 2026 systematic review and meta-analysis screened 7,705 records and included 41 articles representing 64 randomized trials, asking whether the effect of this class varies by age, sex, race, ethnicity, baseline body-mass index or baseline HbA1c. Sex was the rarest subgroup analyzed: only 10 of 48 characterizable trials reported it. Among the six trials that did, covering 19,906 patients, weight loss was 10.9% in women (95% CI, 7.0% to 14.8%) and 6.8% in men (95% CI, 4.6% to 9.0%). No significant heterogeneity was found by age, race, ethnicity, baseline BMI or baseline HbA1c.[5] Sex was the one characteristic that moved the result.
Two large real-world series reproduce it. A retrospective cohort of 1,039 adults who initiated tirzepatide and completed at least twelve months of continuous therapy recorded 15.1% total body weight loss in women against 10.7% in men at fifteen months (p < 0.001). In multivariable analysis female sex was an independent predictor of greater loss, and age was not a predictor at all.[6] A multicenter longitudinal study of 7,847 adults with type 2 diabetes starting a GLP-1 receptor agonist across 18 Italian centers found women lost 1.1 kg more over a median four years (adjusted mean difference, p < 0.001), with 40.0% of women against 30.7% of men reaching a 10% reduction. The gap survived adjustment for weight-adjusted drug dose, so it is not a dosing artifact — and HbA1c reductions were the same in both sexes (mean difference 0.4 mmol/mol, p = 0.21).[7] A single-center series of 114 patients found 51.1% of women against 28.4% of men reached a 5% reduction at twelve months.[8]
The article on what differs between women and men cites a 248-patient cohort that found no significant difference by sex. That is a real null in a small single-center series; the pooled trial estimate above rests on eighty times as many patients and does separate them. Anyone budgeting from the headline figures in the expected weight-loss tool should read the male column as the lower one.
On events, the difference disappears
A 2025 systematic review and meta-analysis pooled sex-stratified data from 11 trials and 85,273 patients, 43,339 of them on a GLP-1 receptor agonist. Three-point major adverse cardiovascular events fell by 14% in men (HR 0.86; 95% CI, 0.79 to 0.93) and 18% in women (HR 0.82; 95% CI, 0.75 to 0.90), with a sex interaction p-value of 0.47. Composite kidney outcomes fell 20% in men (HR 0.80; 0.69 to 0.92) and 31% in women (HR 0.69; 0.54 to 0.87), interaction p = 0.31. Stroke fell 21% and 25%. No significant sex difference appeared for cardiovascular death, myocardial infarction or heart failure hospitalization.[9] The 2026 review of 25 outcome trials reached the same place: MACE hazard 0.89 in men and 0.83 in women with diabetes, and no statistically significant formal interaction anywhere in the pooled ratio of hazard ratios.[4]
A functional endpoint behaves identically. In a post hoc analysis of a phase 3 trial in 792 people with early symptomatic peripheral artery disease and type 2 diabetes — 75.4% male — the improvement in maximum walking distance at 52 weeks favored semaglutide in both sexes, interaction p = 0.65, with pain-free walking distance at interaction p = 0.80 and disease-specific quality of life consistent with the overall trial.[10]
So the shape of the evidence is precise, and it is the opposite of the marketing. The endpoint a cash-pay program sells to men — pounds off — is the one endpoint on which men respond less. The endpoints nobody sells them, and which are the reason the class is in the cardiology guidelines at all, do not distinguish between the sexes. Those outcomes are set out in the cardiovascular article.
How men actually reach the prescription
A nationally representative analysis of the 2019–2022 Medical Expenditure Panel Survey found overall use nearly identical by sex: 0.82% of women and 0.76% of men in 2021–2022, P = 0.96. The route differed sharply. 94.4% of male users carried a type 2 diabetes diagnosis against 86.2% of female users (P = 0.002), and the association between obesity and use was far stronger in women (odds ratio 6.43) than in men (2.04).[11] Men in that survey largely got here through a diabetes diagnosis. Women got here through a weight one.
A cash-pay telehealth service sells the second route to the group that historically used the first. That is the actual product difference, and it is worth naming: for many men the obesity indication is the first time a prescriber has treated the weight itself rather than the glucose. What that changes about the numbers is in the diabetes-versus-weight-loss article.
Where the labels do report a sex split
Two adverse reactions are recorded by sex, and both run the other way. Hair loss on tirzepatide was reported in 7.1% of female against 0.5% of male patients, with placebo at 1.3% and 0% respectively.[2] On semaglutide the same split is 4% against 0.9%.[1] Hip and pelvis fractures in the cardiovascular outcome trial were reported more often on drug than placebo in female patients, 1% against 0.2%.[1] The mechanism behind the first is covered in the hair-loss article. Neither label reports a male-specific adverse reaction of any kind.
Nor does either label report a sex-specific dose. There is no men’s titration schedule, no men’s maintenance dose and no men’s maximum. The reduction in the apnea-hypopnea index in the sleep apnea trials, the one indication studied in a male-majority population, was observed “irrespective of age, sex, ethnicity, baseline BMI, or baseline OSA severity”.[2] Those results are in the sleep apnea article.
What the cash market assumes about men
Of the 277 sellers written up on this site, eleven position the service to men and sixteen run a testosterone or hormone program alongside the GLP-1 one. The site’s own audience boards carry two aimed at women and one aimed at men. None of that reflects a clinical difference, because none exists in the vial: the men’s semaglutide board ranks on state coverage and price structure because there is nothing else to rank on.
The testosterone bundle is the part that deserves scrutiny rather than assumption, since low testosterone in men with obesity is usually a consequence of the weight and usually reverses with it. That evidence is in the testosterone article.
Every figure above comes from trials of FDA-approved product at labeled doses. Most sellers here dispense compounded semaglutide and tirzepatide, which are not FDA-approved and are not reviewed by the FDA for safety, efficacy or quality before they are dispensed, and no compounded product has been studied for a sex difference in anything.
What a man should take from this
Expect a smaller number on the scale than the advertising implies, and do not read it as failure — 6.8% pooled against 10.9% is the trial estimate, not a shortfall. Expect the cardiovascular and kidney benefit to be the same as anyone else’s. Expect no dose, formulation or protocol built for men, because none has been studied. And treat a program that bundles a hormone with the injection as two prescribing decisions rather than one. What separates a careful intake from a checkout is the subject of the red-flags article.